Hepatitis C Virus

Companies enter hepatitis C virus license agreement

Published in Health and Medicine Week, December 1st, 2003

Rigel Pharmaceuticals, Inc., (RIGL) has entered into a nonexclusive licensing agreement with Chiron Corporation (CHIR) granting Rigel a license to discover, develop, and commercialize small molecule therapeutics against certain hepatitis C virus (HCV) drug targets.

The financial terms and other details of the license were not disclosed.

"We believe that Rigel's lead drug candidate, R803, has the potential to become an anchor of therapeutic approaches to treating this intractable virus," stated James M. Gower, chairman and chief executive officer.

Rigel's lead HCV small-molecule drug candidate, R803, rapidly and selectively targets...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2003-12-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry